GlassScriptPhysician profile
Ileana Blackburn
NPI 1275176604
$8,816.68
in general payments reported to CMS, 2019-2025
61 companies · $3,076 in 2025
The $3,076 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,202 · 2022: $704 · 2023: $2,039 · 2024: $1,797 · 2025: $3,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,512 · Education: $399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,512.10 |
| Education | $398.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $782.04 | 2021-2025 | Jakafi, Niktimvo, Monjuvi |
| Daiichi Sankyo INC. | $727.63 | 2023-2025 | Enhertu, Datroway, Vanflyta |
| E.R. Squibb & Sons, L.L.C. | $704.79 | 2021-2025 | Opdivo, Eliquis, Augtyro |
| Merck Sharp & Dohme LLC | $570.66 | 2021-2025 | Keytruda, Welireg, Reblozyl |
| Eisai INC. | $500.71 | 2021-2025 | |
| Astellas Pharma US INC | $432.07 | 2021-2025 | Xtandi, Padcev |
| Lilly USA, LLC | $407.05 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Janssen Biotech, INC. | $397.24 | 2021-2025 | Rybrevant, Erleada, Darzalex |
| Takeda Pharmaceuticals U.S.A., INC. | $378.95 | 2022-2025 | Iclusig, Fruzaqla, Ninlaro |
| Novartis Pharmaceuticals Corporation | $369.78 | 2021-2025 | |
| Beigene USA, INC. | $269.95 | 2021-2025 | Brukinsa, Tevimbra |
| Exelixis INC. | $255.88 | 2021-2025 | Cabometyx |
| Celgene Corporation | $218.11 | 2022-2025 | Reblozyl, Opdualag |
| Glaxosmithkline, LLC. | $211.62 | 2021-2025 | Ojjaara, Shingrix, Blenrep |
| Seagen INC. | $210.22 | 2021-2023 | Tukysa |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $179.39 | 2021-2025 | Lynparza, Calquence, Enhertu |
| Pfizer INC. | $161.18 | 2023-2025 | |
| Abbvie INC. | $154.47 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $126.50 | 2023-2025 | Ultomiris |
| Genentech USA, INC. | $112.55 | 2023-2025 | Tecentriq, Polivy, Columvi |
| Ipsen Biopharmaceuticals, INC | $111.32 | 2022-2024 | Onivyde, Somatuline Depot, Tazverik |
| Genzyme Corporation | $106.90 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $101.33 | 2021-2025 | Libtayo |
| Acrotech Biopharma INC. | $91.42 | 2024-2025 | Beleodaq |
| Bayer Healthcare Pharmaceuticals INC. | $75.58 | 2024-2025 | |
| Deciphera Pharmaceuticals INC. | $71.27 | 2022-2024 | Qinlock |
| Amgen INC. | $70.13 | 2021-2023 | Lumakras, Kyprolis, Blincyto |
| Kite Pharma, INC. | $68.10 | 2021-2024 | Yescarta |
| Emd Serono, INC. | $63.36 | 2023-2025 | Bavencio |
| Genmab U.S., INC. | $58.96 | 2024-2025 | Tivdak, Epkinly |
| Karyopharm Therapeutics INC. | $57.73 | 2023-2024 | Xpovio |
| Aveo Pharmaceuticals, INC. | $56.01 | 2022-2025 | |
| Stemline Therapeutics INC. | $55.06 | 2024-2025 | Orserdu |
| Pharmaessentia USA Corporation | $53.10 | 2025 | Besremi |
| Kyowa Kirin, INC. | $50.65 | 2025 | |
| Sobi, INC | $49.43 | 2023-2024 | |
| Beone Medicines USA, INC. | $40.62 | 2025 | Brukinsa, Tevimbra |
| Novocure INC. | $39.25 | 2024 | Optune Lua (Novottf-200t) |
| Adc Therapeutics America, INC. | $28.72 | 2023-2024 | |
| Foundation Medicine, INC. | $25.16 | 2022-2023 | |
| Mirati Therapeutics, INC. | $24.76 | 2023 | Krazati |
| Avyxa Pharma, LLC | $24.65 | 2025 | |
| Rigel Pharmaceuticals, INC. | $22.81 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Myriad Genetic Laboratories, INC. | $21.59 | 2023 | Bracanalysis Cdx |
| Gilead Sciences, INC. | $19.64 | 2025 | Trodelvy |
| Pharmacosmos Therapeutics INC. | $19.55 | 2023 | Monoferric |
| Taiho Oncology, INC. | $18.58 | 2025 | |
| Celltrion USA INC. | $17.64 | 2025 | Vegzelma |
| Springworks Therapeutics, INC. | $17.25 | 2025 | Ogsiveo |
| Tersera Therapeutics LLC | $17.18 | 2025 | Quzyttir |
| Puma Biotechnology, INC. | $16.87 | 2023 | |
| Myovant Sciences INC. | $16.87 | 2022 | |
| Tempus Ai, INC | $16.37 | 2024 | |
| Coherus Oncology, INC. | $16.06 | 2023 | |
| Syndax Pharmaceuticals, INC. | $15.99 | 2025 | Revuforj |
| Epizyme, INC. | $15.52 | 2021 | |
| Amneal Pharmaceuticals LLC | $15.00 | 2023 | Avastin |
| Stryker Corporation | $14.85 | 2025 | Clottriever Bold Catheter |
| Geron Corporation | $13.85 | 2025 | Rytelo |
| Array Biopharma INC | $13.82 | 2023 | Xalkori, Lorbrena, Braftovi |
| Tactile Systems Technology INC | $12.94 | 2023 | Flexitouch Plus, Entre Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ileana Blackburn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.